PMID- 19270464 OWN - NLM STAT- MEDLINE DCOM- 20090522 LR - 20220310 IS - 1423-0224 (Electronic) IS - 0302-282X (Linking) VI - 59 IP - 1 DP - 2009 TI - Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. PG - 51-8 LID - 10.1159/000205518 [doi] AB - BACKGROUND: Some neurotropins, including brain-derived neurotropic factor (BDNF) or nerve growth factor-beta (beta-NGF), play important roles in neurodevelopment and neuroprotection. We examined the plasma levels of these 2 factors in schizophrenia patients at the time of admission and after 6 weeks of treatment with risperidone. METHODS: Plasma BDNF and beta-NGF levels were measured in 36 schizophrenia patients and 36 healthy controls. All the patients underwent 6 weeks of treatment with risperidone. The severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS). We compared plasma BDNF and beta-NGF levels among much-improved (n = 13, 36.1%, > or =50% PANSS score reduction), minimal-improved (n = 15, 41.7%, > or =25% and <50% PANSS score reduction) and nonresponse patients (n = 8, 22.2%, <25% PANSS score reduction). RESULTS: At baseline, plasma BDNF had no significant difference between schizophrenia patients and controls, but beta-NGF levels were significantly lower in schizophrenia patients than controls (p = 0.037). Plasma BDNF and beta-NGF in all schizophrenia patients had no significant changes between pre- and posttreatment. Baseline BDNF levels were significantly lower in nonresponse patients than others (p = 0.038). After treatment, much-improved patients had significantly higher plasma BDNF than nonresponse patients (p = 0.023). However, beta-NGF levels had no significant differences between them. CONCLUSIONS: Our data suggest that higher plasma BDNF levels might be associated with better response to risperidone treatment, while plasma beta-NGF levels might have no effect on the clinical response in schizophrenia patients. CI - Copyright 2009 S. Karger AG, Basel. FAU - Lee, Bun-Hee AU - Lee BH AD - Department of Psychiatry, College of Medicine, Korea University, Ansan, Korea. FAU - Kim, Yong-Ku AU - Kim YK LA - eng PT - Journal Article DEP - 20090306 PL - Switzerland TA - Neuropsychobiology JT - Neuropsychobiology JID - 7512895 RN - 0 (Antipsychotic Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 9061-61-4 (Nerve Growth Factor) RN - L6UH7ZF8HC (Risperidone) SB - IM MH - Adult MH - Analysis of Variance MH - Antipsychotic Agents/*therapeutic use MH - Brain-Derived Neurotrophic Factor/*blood MH - Female MH - Humans MH - Male MH - Nerve Growth Factor/*blood MH - Psychiatric Status Rating Scales MH - Risperidone/*therapeutic use MH - Schizophrenia/*blood/*drug therapy MH - Treatment Outcome EDAT- 2009/03/10 09:00 MHDA- 2009/05/23 09:00 CRDT- 2009/03/10 09:00 PHST- 2008/07/01 00:00 [received] PHST- 2008/11/28 00:00 [accepted] PHST- 2009/03/10 09:00 [entrez] PHST- 2009/03/10 09:00 [pubmed] PHST- 2009/05/23 09:00 [medline] AID - 000205518 [pii] AID - 10.1159/000205518 [doi] PST - ppublish SO - Neuropsychobiology. 2009;59(1):51-8. doi: 10.1159/000205518. Epub 2009 Mar 6.